Home > Insider Trading > Filing (0001181431-13-028818)

Filing Details

Accession Number:: 0001181431-13-028818
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-05-17 18:58:06
Reporting Period:: 2013-05-07

Filing Date:: 2013-05-17
Accepted Time:: 2013-05-17 18:58:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
861838	Idera Pharmaceuticals Inc.	IDRA	Biological Products, (No Disgnostic Substances) (2836)	043072298

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1562070	Umari Abdul-Wahab	C/O Idera Pharmaceuticals, Inc. 167 Sidney Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-05-07	2,600,000	$0.00	0	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2013-05-07	2,400,000	$0.00	0	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Acquisiton	2013-05-07	1,000,000	$0.00	1,000,000	$0.61
Common Stock	Warrants	Acquisiton	2013-05-07	575,758	$0.00	575,758	$0.79
Common Stock	Warrants	Acquisiton	2013-05-07	313,341	$0.00	313,341	$0.79
Common Stock	Warrants	Acquisiton	2013-05-07	110,901	$0.00	110,901	$0.79
Common Stock	Warrants	Acquisiton	2013-05-07	2,600,000	$0.00	2,600,000	$0.47
Common Stock	Warrants	Acquisiton	2013-05-07	2,400,000	$0.00	2,400,000	$0.47

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2013-05-07	2018-05-07	No	4	A	Indirect
2013-05-07	2014-06-01	No	4	A	Indirect
2013-05-07	2014-06-01	No	4	A	Indirect
2013-05-07	2014-06-01	No	4	A	Indirect
2013-05-07	2018-05-07	No	4	P	Indirect
2013-05-07	2018-05-07	No	4	P	Indirect

Footnotes

On May 7, 2013, upon the consummation of a public offering of the Issuer (the "Offering"), Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner, acquired, directly from the Issuer, warrants to purchase up to 1,575,758 shares of common stock (the "Pillar I Shares") of the Issuer.
On May 7, 2013, upon the consummation of the Offering, Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner, acquired, directly from the Issuer, warrants to purchase up to 313,341 shares of common stock (the "Pillar II Shares") of the Issuer.
On May 7, 2013, upon the consummation of the Offering, Participations Besancon ("Besancon"), a fund advised by Pillar GP, acquired, directly from the Issuer, warrants to purchase up to 110,901 shares of common stock (the "Besancon Warrants").
Abdul-Wahab Umari is a director of Pillar GP and serves as the representative of a Pillar I, Pillar II, Pillar III and Pillar GP on the Issuer's board of directors. Mr. Umari disclaims Section 16 beneficial ownership of the Pillar I Shares, Pillar II Shares, Pillar III Shares, Besancon Warrants and Besancon Shares and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. Umari owns directly 46,117 shares of common stock of the Issuer.
On May 7, 2013, upon the consummation of the Offering, Pillar Pharmaceuticals III, L.P. ("Pillar III"), of which Pillar GP is the general partner, acquired, in the Offering, 2,600,000 shares of common stock and warrants to purchase up to 2,600,000 shares of common stock (the "Pillar III Shares") of the Issuer.
On May 7, 2013, upon the consummation of the Offering, Participations Besancon acquired, in the Offering, 2,400,000 shares of common stock and warrants to purchase up to 2,400,000 shares of common stock (the "Besancon Shares").